Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
22 févr. 2024 07h31 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life...
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
22 févr. 2024 07h30 HE
|
Ocular Therapeutix, Inc.
Industry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair Jeffrey S. Heier, MD to become Chief Scientific Officer, Peter K. Kaiser, MD to be Medical Director, and Sanjay...
Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
15 févr. 2024 08h00 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
13 févr. 2024 07h37 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
25 janv. 2024 08h00 HE
|
Ocular Therapeutix, Inc.
SPA amendment expands eligibility criteria for SOL clinical trial Broadening of eligibility criteria anticipated to accelerate overall trial enrollment BEDFORD, Mass., Jan. 25, 2024 (GLOBE...
Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
18 déc. 2023 16h01 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization...
Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
13 déc. 2023 22h09 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization...
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
13 déc. 2023 16h01 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization...
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
08 nov. 2023 08h00 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update
07 nov. 2023 16h01 HE
|
Ocular Therapeutix, Inc.
FDA Agrees to Overall Design of the First Pivotal Trial for AXPAXLI in Wet AMD under a Special Protocol Assessment; Expect First Subject Dosed by Year-End Top-line Data from U.S.-based HELIOS Trial...